Human Fatty-Liver Model Cells for VLDL-Based Dyslipidemia Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Non-human animal models for fatty liver disease require significant time, labor, and resources, and suffer from individual variability and ethical concerns, making them unsuitable for efficient investigation of fatty liver onset and treatment.
Innovation Solution
Development of human fatty-liver model cells that maintain fatty liver symptoms, such as fat droplet accumulation, by culturing human hepatocytes in a medium containing dimethyl sulfoxide, which allows for the screening of substances based on VLDL content in the culture supernatant.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-human animal models are used to study fatty liver, then fatty liver symptoms can be observed, but significant time, labor, and resources are required plus individual variability and ethical concerns arise
Solution Approach 1:
The patent creates an in vitro cell culture model that copies the essential characteristics of fatty liver disease in human hepatocytes, eliminating the need for complex animal models. The cell model maintains fat droplet accumulation and lipid metabolism features while being much simpler to prepare and scale.
Solution Approach 2:
The patent extracts and isolates human hepatocytes from fatty liver tissue, then cultures them in a controlled in vitro environment. This extraction allows the study of fatty liver mechanisms without requiring entire animal models, significantly reducing time and resource requirements.
2Reliability
If human hepatocytes are cultured in vitro, then fatty liver symptoms can be maintained, but the cells cannot maintain fat droplet accumulation without specific culture conditions
Solution Approach 1:
The patent modifies culture medium parameters by adding specific substances (such as fatty acids, cholesterol, or other lipid-rich components) to maintain fat droplet accumulation in human hepatocytes. These parameter changes enable the cells to sustain fatty liver characteristics during in vitro culture.
Solution Approach 2:
The patent introduces intermediary substances in the culture medium that facilitate lipid accumulation and maintain fatty liver phenotypes. These intermediaries (such as lipid supplements or specific growth factors) mediate between the culture environment and the cells' lipid metabolism to preserve disease characteristics.
3Reliability
If human hepatocytes are cultured in vitro, then individual variability is eliminated, but the system becomes more complex requiring precise medium composition
Solution Approach 1:
The patent establishes specific parameter ranges for culture medium composition (concentrations of lipids, sugars, amino acids, and other components) that optimize both reproducibility and feasibility. By defining these parameters, the system achieves consistent results while remaining practically implementable.
Data Source
AI summary
An object of the present invention is to provide human fatty-liver model cells exhibiting symptoms of fatty-liver tissue that can be used for a method for screening for a substance having an effect on dyslipidemia including fatty liver and the present invention provides human fatty-liver model cells for use in a method for screening for a substance having an effect on dyslipidemia based on an increase/decrease of very low density lipoprotein (VLDL) in culture supernatant as an index, in which the culture supernatant of the cells contains VLDL and low density lipoprotein (LDL), in which the VLDL is contained more than the LDL.